NewImage

You thought the Shark Tank was tough…
Wait until you enter the the BioHealth Capital Region Crab Trap!

Submit your application for the opportunity to present your innovation and be named the region’s early stage biohealth company with the most commercial potential at the 2019 BioHealth Regional Forum, $10,000, and MORE!

Application Deadline: March 1, 2019

Finalists will be announced: March 21st, 2019

Finalist Presentations BioHealth Capital Region Forum event: April 9th, 2019

Submit Application »

GlaxoSmithKline-gsk-logo

The partners at SR One, a storied corporate biotech VC with investments across a wide range of drug developers on both sides of the Atlantic, are engaged in talks to split away from the pharma giant GlaxoSmithKline, according to sources familiar with a move that’s been in the works since at least late last year.

bhi sbir logo

HOLD THE DATE – February 28, 2019  8 am. – 3:00 p.m.

Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!) 

8-8:30 Networking and Registration

8:30 – 12:00 p.m. – Program Overviews

12:00 p.m. – 1:00 p.m. – Networking Lunch

1:00 p.m. – 3:00 p.m – 1:1 Meetings with Program Managers*

Agencies represented include:   
NSF, NIH NIA, NIH NCI, NIH NHLBI, NIH NIDA, US Army (invited)


*The program overview will be available by videoconference.

**You do not have to participate in 1:1 meetings.  However, to do so, you must attend the overview session in person.
PRE-REGISTRATION IS REQUIRED:  RSVP by noon 2/26:  This email address is being protected from spambots. You need JavaScript enabled to view it.

invest-money-vc-fives-pixa

After weeks of speculation that biopharma deal making would cool off, 2019 got off to a flying start as far as mergers-and-acquisitions (M&A) is concerned, thanks to two blockbuster transactions: Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene, followed four days later by Eli Lilly’s planned $8 billion purchase of Loxo Oncology—a deal that quickly became the buzz of the J.P. Morgan 37th Healthcare Conference, held earlier this month in San Francisco.

NewImage

Our National Cancer Institute-University of Maryland (NCI-UMD) Partnership for Integrative Cancer Research reflects the broad interests of our participating NCI and UMD researchers. We are delighted to invite you to our annual NCI-UMD Partnership for Integrative Cancer Research Symposium on Friday, February 8th from 10am-4pm which will take place in Bethesda, Maryland in the John Edward Porter Neuroscience Research Center at the National Institutes of Health, Bldg 35A, Room 620/630. Please register and plan to participate in our October symposium. The final agenda will be announced shortly.

academic-research-books-pixa

The past decade has seen intensified research collaboration between pharmaceutical companies and academic institutions. Although such partnerships are recognized as a source of innovation and a key pillar to advance science in drug discovery, they are replete with challenges. Despite much anecdotal evidence and debate, fact-based evidence on the nature of these challenges and how to manage them is scarce.

Deloitte-logo

Deloitte has surpassed its peers to become the world's most valuable professional services brand, according to the 2019 Global 500 report issued by Brand Finance on 22 January 2019. Deloitte's strong performance was due to higher scores in Brand Finance's metrics of familiarity, consideration, satisfaction, preference, recommendation and revenue.   

disease-heart-health-pixa

2019 has kicked off with a wave of innovative health care solutions highlighted at mega-conferences like CES and the J.P. Morgan Healthcare Conference - from the introduction of the first wearable blood pressure monitor to virtual home health care for seniors to online vision tests allowing patients to renew prescriptions from anywhere at anytime. We are truly living through an age of disruption spurred by technological advances.

united-therapeutics-logo

United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).  Upon closing, United Therapeutics paid Arena $800 million. Arena is also entitled to potential milestone payments of up to $400 million based on the achievement of certain regulatory events as well as low double-digit tiered royalties on annual net sales of ralinepag products.    

doerfler-doug-maxcyte-image

Cell therapy offers a treasure chest of new medicines, but there is still much to learn about cell activities and how to deliver these potential benefits before science and the industry can fully fulfill on their promise. One of cell therapy’s earliest pioneering companies is MaxCyte, based in Gaithersburg, MD and in the United Kingdom.  Leading MaxCyte is president and CEO Doug Doerfler, a biotech pioneer who has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was also a founder of MaxCyte in July 1998.

body-parts-veins-organs-pixa

Colorectal cancer (CRC) is one of the leading causes of death in the western society, being ranked third most lethal neoplasia in the United States in both men and women.1 In 2014, the American Cancer Society estimated that approximately 136,830 new cases of CRC will be diagnosed in the United States, with more than 50,000 Americans expected to die due to disease progression or complications.1,2 The lifetime cancer-related costs are considerable and differ by cancer site, disease stage, age at diagnosis, and treatment phase. Considering direct healthcare costs, CRC is the second most important neoplasia with estimated expenses of more than $14 billion.3,4

maryland tech council 2018 logo

One major focus for legislators during this year’s session is how to bring down the cost of health care, as everyday Marylanders struggle to afford the cost they pay at the pharmacy counter. Despite disagreements between different groups within and beyond health care, there is broad consensus that something must be done about the cost patients pay without denying Marylanders the world-class treatments available to them, many of which are made right here in Maryland.

NewImage

The FDA is witnessing a surge of cell and gene therapy products entering early development, evidenced by a large upswing in the number of investigational new drug (IND) applications. Based on this activity, we anticipate that the number of product approvals for cell and gene therapies will grow in the coming years, reflecting significant scientific advancement and the clinical promise of these new innovations.

johns-hopkins-hospital-logo

Researchers at the Johns Hopkins University School of Medicine have been awarded $2.1 million by the U.S. Centers for Disease Control and Prevention to study whether paying patients to take their medicine and tracking their doses with video software can help patients stick with their treatment for opioid addiction.

brca-exchange-logo

A global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes is available to the public. The BRCA Exchange was created through the BRCA Challenge, a long-term demonstration project initiated by the Global Alliance for Genomics and Health (GA4GH) to enhance sharing of BRCA1 and BRCA2 data. The resource, available through a website and a new smartphone app, allows clinicians to review expert classifications of variants in these major cancer predisposition genes as part of their individual assessment of complex questions related to cancer prevention, screening, and intervention for high-risk patients.

vitus-vet-logo

There’s an app for everything these days — including a plethora for people with pets.

Thanks to the streamlined design of most current apps, you don’t have to be technically savvy to know how to download and use them on your smartphones or tablets.

lupin-pharmaceuticals-logo

Pharma major Lupin announced that it has received approval for its Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg,  88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc’s Synthroid Tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg.

William E. Bentley is the Robert E. Fischell Distinguished Chair of Engineering and the Inaugural Director of the Robert E. Fischell Institute for Biomedical Devices. He is appointed in the Fischell Department of Bioengineering as well as the Department of Chemical and Biomolecular Engineering at the University of Maryland, College Park and the Institute for Bioscience and Biotechnology Research. At Maryland since 1989, Dr. Bentley has focused his research on the development of molecular tools that facilitate the expression of biologically active proteins and on materials incorporated into biomedical devices, having authored over 300 related archival publications

He is a fellow of AAAS, ACS, AIMBE, and the American Academy of Microbiology. He has served on advisory committees for the NIH, NSF, DOD, DOE, FDA, USDA, and several state agencies and has mentored over 40 PhDs and 25 postdocs, many now in leadership roles within industry (24), federal agencies (5) and academia (26). He co-founded a protein manufacturing company, Chesapeake PERL, based on insect larvae as mini bioreactors.

Listen now on iTunes Google Play , and TuneIn

funding-money-invest-pixa

To those who have been following the space, it’s no surprise that 2018 has been a record year for venture capital investing in healthcare. With $28.8 billion raised through the end of November (and big deals like the $400 million Series C raised by Relay Therapeutics last week) startups in the sector have raised more money this year than any year before in the last 10 years that VC funding database Pitchbook has tracked investments in the space.

university-system-of-maryland-usm-2-logo

Maryland universities are creating new academic programs they say could help the state adapt to a changing innovation economy and help meet needs for tomorrow's educators. The Education Policy and Student Life committee of the University System of Maryland’s Board of Regents moved forward this week with eight new programs proposed from system universities.